Publications by authors named "K Kurimoto"
Objectives: Gemcitabine and nab-paclitaxel combination therapy (GnP) is a standard treatment for unresectable or recurrent pancreatic cancer. However, fatigue and malaise are frequent adverse effects. Recently, Kampo medicine containing ginsenoside has been reported to relieve cancer-related fatigue.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the link between molecular changes in pancreatic ductal adenocarcinoma (PDAC) and local invasiveness, emphasizing the importance of identifying gene profiles that predict surgical margin positivity to improve surgical outcomes.
- - Researchers compared genome-wide miRNA expressions between positive and negative molecular surgical margins (MSM) and found that high levels of miR-210-3p are significantly associated with poor recurrence-free survival, larger tumor size, and increased metastasis.
- - The findings indicate that inhibiting miR-210-3p in PDAC cell lines reduces cancer cell growth and invasiveness, with ISCU identified as a target gene affected by miR-210-3p, suggesting potential avenues for therapeutic interventions
Background/aim: Organs of the digestive system are frequent sites of cancer development, and digestive tract cancers are the leading causes of death worldwide, including in Japan. Most of these cancers are associated with smoking or drinking habits. This study focused on the clinical and genomic characteristics of patients with these cancers using the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which comprises a large volume of data on Japanese patients who have undergone tumor profiling gene panel tests.
View Article and Find Full Text PDFSingle-cell RNA sequencing (scRNA-seq) combined with laser capture microdissection (LCM) offers a versatile framework for comprehensive transcriptomics from tissue sections. Here, we present a detailed protocol for DRaqL (direct RNA recovery and quenching for LCM) in combination with Smart-seq2 (DRaqL-Smart-seq2), which enables high-quality RNA sequencing for single cells obtained from alcohol-fixed murine ovarian sections. Additionally, we provide an optional procedure for scRNA-seq from formalin-fixed sections (DRaqL-Protease-Smart-seq2).
View Article and Find Full Text PDFBackground: The alpha emitter astatine-211 (At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (I). Herein, we aimed to establish a robust method for the manufacturing and quality control of [At]NaAt solution for intravenous administration under the good manufacturing practice guidelines for investigational products to conduct an investigator-initiated clinical trial.
Results: At was separated and purified via dry distillation using irradiated Bi plates containing At obtained by the nuclear reaction of Bi(He, 2n)At.